CA-SKYFLOW
Today Skyflow, the data privacy vault company, announced new data residency capabilities including Asia-Pacific instances in Japan, Indonesia, India, and Bahrain, and an expansion of its footprint in EMEA and North America.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230526005072/en/
(Graphic: Business Wire)
With Skyflow, companies that store sensitive customer data can meet regulatory requirements for localized storage, provable and auditable data protection, and governance – simply by leveraging Skyflow’s global vault infrastructure. This enables global expansion to reach new customers in new markets, while minimizing complexity and cost. For example, SaaS ISVs can scale and sell their product in both EMEA and APAC without adding instances.
Replicating Instances is Expensive and Slow
Today, companies that want to expand internationally face a technically complex and expensive proposition: replicate all of your cloud infrastructure, databases, and data warehouses by adding instances in each region before onboarding new customers in that region.
As more countries implement data protection laws, some businesses that were previously compliant now face the need to re-architect their customer data platform (CDP) and cloud infrastructure.
With Skyflow, companies have a better option: add a data privacy vault in each region with data localization requirements, and store sensitive customer data in that local vault. Skyflow’s unique polymorphic encryption and tokenization capabilities let you do this without losing the ability to run workflows, analytics, or even machine learning while maintaining compliance.
Launch in New Regions in Weeks
One Skyflow customer, a Fortune 500 computer hardware company, was able to launch a new product in 30 countries across six regions in just three weeks without replicating their CDP or cloud infrastructure. They provisioned Skyflow vaults in each region, and stored their customer PII locally, all using Skyflow’s simple, yet powerful API.
“Our customers love that they can run their businesses globally without worrying about expensive replication and duplication. By isolating the PII and storing it locally, they meet localization requirements and also enhance security and governance controls,” said Anshu Sharma, co-founder and CEO of Skyflow. “We run a global network of cloud infrastructure so you don’t have to.”
“Skyflow enabled us to set up vaults in different regions quickly – such as Bahrain and the UAE – without having to spend money and resources replicating our infrastructure. Implementation was easy, so we were able to quickly start supporting customers across EMEA while ensuring privacy and compliance," said Michael Tomlins, co-founder and CEO of Apaya.
Read about Skyflow’s data residency solution here.
About Skyflow
Skyflow is a data privacy vault company built to radically simplify how companies isolate, protect and govern their customers’ most sensitive data. With its global network of data privacy vaults, Skyflow helps companies meet complex data localization requirements. Skyflow customers span verticals like fintech, retail, travel, and healthcare. Skyflow is headquartered in Palo Alto, California and was founded in 2019. For more information, visit www.skyflow.com or follow on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230526005072/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom